By David Tuller, DrPH As I have recently written, four major clinical trials of CBT for so-called MUS have documented the opposite of what the investigators hoped to prove. In fact, the evidence from this research suggests that CBT is not an effective treatment for these conditions. That hasn’t stopped these investigators from claiming otherwise, …
By David Tuller, DrPH While some medical professionals argue that prolonged non-specific symptoms after acute COVID-19 are psychogenic and that “Long COVID” as a presumed clinical entity was concocted by a cabal of queers and feminists, others are getting on with efforts to disseminate more appropriate information to their colleagues. These efforts often involve drawing …
By David Tuller, DrPH A Final Round in Norway Lightning Process supporters got some bad news recently when a Norwegian national research ethics panel rejected a proposed study because it was poorly designed and fraught with conflicts of interest, as I wrote about here. But that wasn’t the end of the drama. Although the ethics …
By David Tuller, DrPH My friend and colleague Steven Lubet is a professor of law at Northwestern University. He and I have collaborated on a number of articles, including a response to Professor Michael Sharpe’s views on so-called “medically unexplained symptoms” in the journal Medical Humanities and a piece on links between ME/CFS and Long …
Trial By Error: Professor Steven Lubet on Misogyny, Homophobia and Long COVID Denialism Read More »
By David Tuller, DrPH A year ago, I wrote a post about how the biopsychosocial ideological brigades had completed a trifecta of major studies that investigated cognitive behavior therapy for a variety of so-called “medically unexplained symptoms” (MUS). As a group, the studies demonstrated the overall ineffectiveness of CBT as a treatment for this category …
By David Tuller, DrPH I have pressed the Journal of Psychosomatic Research to correct a recent paper, “Guided graded exercise self-help for chronic fatigue syndrome: Long term follow up and cost-effectiveness following the GETSET trial.” The senior author is Professor Peter White. Now the journal has published a revised “Highlights” section of the paper that …
